Preferred Label : Riltozinameran/Tozinameran;
NCIt definition : A bivalent booster vaccine consisting of tozinameran, lipid nanoparticle (LNP) encapsulating
a nucleoside modified messenger RNA (modRNA) encoding an optimized form of the full-length
viral spike (S) glycoprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
Wuhan-Hu-1 strain (Original), and riltozinameran, a LNP encapsulating a modRNA encoding
an optimized form of the full-length viral S protein of the SARS-CoV-2 Omicron variant
B.1.1.529, with potential immunizing and anti-COVID-19 activities. Upon injection
of riltozinameran/tozinameran, the LNPs bind to the plasma membrane of nearby cells
and release SARS-CoV-2 S protein mRNA into the cells. The mRNA is then translated
by the cellular protein translation machinery to produce SARS-CoV-2 S protein. This
may activate both humoral and cellular immune responses which may result in protection
against SARS-CoV-2 infection.;
Drug name : Comirnaty Original/Omicron BA.1;
NCI Metathesaurus CUI : CL1798635;
Origin ID : C189806;
UMLS CUI : C5708758;
Semantic type(s)
- concept_is_in_subset
